首页> 美国卫生研究院文献>Journal of Drug Delivery >Volatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections
【2h】

Volatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections

机译:挥发性酸溶剂蒸发(VASE):阿昔洛韦的分子均质分布在可生物蚀解的聚合物基质中用于长期治疗单纯疱疹病毒1感染。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Treatment for herpes simplex virus-1 and -2 (HSV-1 and -2) patients who suffer from recurrent outbreaks consists of multiple daily doses of the antiviral drugs acyclovir (ACV), penciclovir, or their more orally bioavailable derivatives valacyclovir or famciclovir. Drug troughs caused by missed doses may result in viral replication, which can generate drug-resistant mutants along with clinical sequelae. We developed a molecularly homogeneous mixture of ACV with the bioerodable polymer polycaprolactone. Through scanning electron microscopy, infrared spectroscopy, gel permeation chromatography, 1H NMR, and differential scanning calorimetry, our method of combining drug and polymer, termed Volatile Acid-Solvent Evaporation (VASE), does not compromise the integrity of polymer or drug. Furthermore, VASE creates materials that deliver therapeutic amounts of drug consistently for approximately two months. Devices with high enough drug loads diminish primary infection of HSV-1 in Vero cells to the same level as seen with a single dose of ACV. Our data will lead to further experiments in animal models, demonstrating efficacy in preventing reactivation of these viruses with a single intervention, and with other antiviral drugs amenable to such manipulation. Additionally, this type of treatment would leave no trace after its useful lifetime, as drug is released and polymer matrix is degraded in vivo.
机译:对于反复发作的单纯疱疹病毒1和-2(HSV-1和-2)患者的治疗包括每天多次服用抗病毒药阿昔洛韦(ACV),喷昔洛韦或更口服可利用的衍生物伐昔洛韦或泛昔洛韦。剂量不足造成的药槽可能会导致病毒复制,从而产生耐药性突变体以及临床后遗症。我们开发了ACV与可生物侵蚀的聚合物聚己内酯的分子均质混合物。通过扫描电子显微镜,红外光谱,凝胶渗透色谱,1H NMR和差示扫描量热法,我们将药物和聚合物结合的方法称为挥发性酸溶剂蒸发(VASE),不会损害聚合物或药物的完整性。此外,VASE还创建了可在大约两个月的时间内持续输送治疗量药物的材料。具有足够高药物负荷的设备可将Vero细胞中HSV-1的原发感染减少到与单剂量ACV相同的水平。我们的数据将导致在动物模型中进行进一步的实验,证明通过单一干预以及适用于此类操作的其他抗病毒药物,可以有效防止这些病毒的再激活。另外,随着药物的释放和聚合物基质的体内降解,这种类型的治疗在其使用寿命后将不会留下任何痕迹。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号